The Aβ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of Aβ1-42 on LTP even following serial dilution to a 500:1 stoichiometric excess of Aβ1-42, suggesting a beneficial prion-like seeding mechanism

Neuropharmacology. 2020 Nov 15:179:108267. doi: 10.1016/j.neuropharm.2020.108267. Epub 2020 Aug 3.

Abstract

MRZ-99030 (GAL-101) is a small molecule that promotes the formation of off-pathway, non-toxic amorphous clusters of Aβ thereby reducing the amount of toxic soluble oligomeric Aβ species. MRZ-99030 clearly prevents synaptotoxic effects of Aβ1-42 oligomers on synaptic plasticity and cognition. Long lasting in vivo effects indicate that MRZ-99030 seeds a beneficial self-replication of non-toxic Aβ aggregates - "trigger effect". To test this, we prepared a serial dilution of MRZ-99030 starting with a 20:1 stoichiometric excess to Aβ1-42. After incubating the Aβ1-42/MRZ-99030 mixture for 20 min, 10% was transferred to a freshly prepared Aβ1-42 solution. This dilution step was repeated 3 times finally resulting in a 500:1 stoichiometric excess of Aβ1-42 over MRZ-99030. This solution was tested for its ability to impair long-term potentiation (LTP) in CA1 neurons. Even following serial dilution, MRZ-99030 prevented the synaptotoxic effect of Aβ1-42 on CA1-LTP after tetanic stimulation of the Schaffer collaterals whereas incubation with MRZ-99030 (0.1 nM) without serial dilution did not prevent the synaptic deficits caused by Aβ1-42 (50 nM). Time course experiments revealed that this protective effect was still evident even when the serially diluted Aβ1-42/MRZ-99030 mixture was prepared up to 1 week before the LTP experiment. MRZ-99030, when serially diluted with Aβ1-42, was also capable of detoxifying/reversing an already established neurotoxic process. In TEM experiments, Aβ oligomers/annular protofibrils were converted to amorphous Aβ clusters following incubation with serially diluted MRZ-99030 to a final concentration of MRZ-99030 (20 nM) and Aβ1-42 (10 μM).

Keywords: AMD; Age related macular degeneration; Alzheimer's disease; D-Trp-Aib; GAL-101; Glaucoma; LTP; Long term potentiation; MRZ-99030; Oligomers; TEM; Transmission electron microscopy; β-amyloid.

MeSH terms

  • Amyloid beta-Peptides / antagonists & inhibitors
  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Brain / drug effects
  • Brain / metabolism
  • Brain / pathology
  • Dipeptides / pharmacology*
  • Excitatory Postsynaptic Potentials / drug effects*
  • Excitatory Postsynaptic Potentials / physiology
  • Long-Term Potentiation / drug effects*
  • Long-Term Potentiation / physiology
  • Mice
  • Mice, Inbred C57BL
  • Organ Culture Techniques
  • Peptide Fragments / antagonists & inhibitors
  • Peptide Fragments / toxicity*
  • Prion Proteins* / metabolism
  • Synapses / drug effects*
  • Synapses / metabolism
  • Synapses / pathology

Substances

  • 2-(2-amino-3-(1H-indol-3-yl)propionylamino)-2-methylpropionic acid
  • Amyloid beta-Peptides
  • Dipeptides
  • Peptide Fragments
  • Prion Proteins
  • amyloid beta-protein (1-42)